Taking on-board the Alexion acquisition
21/07/21 -"AstraZeneca has completed the acquisition of Alexion Pharmaceuticals (US rare diseases specialist). Given that rare diseases are a high-growth and attractive margin area (even ahead of oncology), ..."
Pages
68
Language
English
Published on
21/07/21
You may also be interested by these reports :
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...
13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...
12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...